Previous 10 | Next 10 |
VBI Vaccines Inc. (VBIV) is expected to report $-0.14 for Q3 2023
2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...
Preclinical data suggests novel mRNA-launched eVLPs (“MLE”) generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone In addition to immunologic benefits, new MLE technology enables manufacturing of particulate vaccines on an accel...
First clinical data from a pan-coronavirus vaccine candidate Elicited high and sustained neutralizing responses against a panel of COVID-19 variants, including Wuhan, Delta, Beta, Omicron BA.5, as well as multiple animal coronaviruses including bat and pangolin variants Durability of prot...
Multi-center, randomized, controlled, open-label study to enroll up to 60 patients with first recurrent GBM FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in the recurrent setting, following encouraging Phase 1/2a study results Interim data ana...
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased seroconversion rate is strongly associated with BRII-179 (VBI-2601) treatment and correlates with the increased rate of...
2023-09-06 07:33:44 ET More on VBI Vaccines VBI Vaccines slides on discounted stock and warrants offering VBI Vaccines down 3% after hours on public offering VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook For further details see: ...
2023-08-14 09:01:49 ET VBI Vaccines press release ( NASDAQ: VBIV ): Q2 GAAP EPS of -$5.05 misses by $2.89 . Revenue of $0.74M (+111.4% Y/Y) misses by $0.19M . For further details see: VBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M miss...
PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 Expanded hepatitis B collaboration with Brii Biosciences announced in July for $15 million upfro...
VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public offering of common shares and accompanying common warrant...
News, Short Squeeze, Breakout and More Instantly...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone Early data from randomize...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...